ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Exagen Diagnostics, Inc.™ today announced that it filed for U.S. Food and Drug Administration (FDA) review of the first of six products currently in the Exagen™ pipeline. This product, eXagenBC™, is a DNA-based test that identifies risk of recurrence in breast cancer patients and allows physicians to more accurately predict prognostic outcome.
